Literature DB >> 20184583

The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation.

M J Escámez1, M García, N Cuadrado-Corrales, S G Llames, A Charlesworth, N De Luca, N Illera, C Sánchez-Jimeno, A Holguín, B Duarte, M J Trujillo-Tiebas, J L Vicario, J L Santiago, A Hernández-Martín, A Torrelo, D Castiglia, C Ayuso, F Larcher, J L Jorcano, A Meana, G Meneguzzi, G Zambruno, M Del Rio.   

Abstract

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a genodermatosis caused by mutations in COL7A1. The clinical manifestations are highly variable from nail dystrophy to life-threatening blistering, making early molecular diagnosis and prognosis of utmost importance for the affected families. Mutation identification is mandatory for prenatal testing.
OBJECTIVES: To conduct the first mutational analysis of COL7A1 in a Spanish cohort, to assess mutation consequences at protein/mRNA level and to establish genotype-phenotype correlations.
METHODS: Forty-nine Spanish patients with DEB were studied. Antigen mapping was performed on patient skin biopsies. COL7A1 mutation screening in genomic DNA was performed by polymerase chain reaction (PCR) and direct sequencing. Mutation consequences were determined by reverse transcriptase-PCR.
RESULTS: Eight patients belonged to three unrelated families with dominant DEB. Forty-one were affected with recessive DEB (RDEB). Specifically, 27 displayed the severe generalized subtype, eight the other generalized subtype and six a localized phenotype (two pretibial, three acral and one inversa). Thirty-five mutations were identified, 20 of which are novel. The pathogenic mutation c.6527insC accounted for 46.3% of Spanish RDEB alleles. A consistent genotype-phenotype correlation was established.
CONCLUSIONS: Although the COL7A1 database indicates that most DEB mutations are family specific, the pathogenic mutation c.6527insC was highly recurrent in our cohort. This level of recurrence for a single genetic defect has never previously been reported for COL7A1. Our findings are essential to the clinicians caring for patients with DEB in Spain and in the large population of Spanish descendants in Latin America. They also provide geneticists a molecular clue for a priority mutation screening strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184583     DOI: 10.1111/j.1365-2133.2010.09713.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Probability of high-risk genetic matching with oocyte and semen donors: complete gene analysis or genotyping test?

Authors:  Marta Molina Romero; Alberto Yoldi Chaure; Miguel Gañán Parra; Purificación Navas Bastida; José Luis Del Pico Sánchez; Ángel Vaquero Argüelles; Paloma de la Fuente Vaquero; Juan Pablo Ramírez López; José Antonio Castilla Alcalá
Journal:  J Assist Reprod Genet       Date:  2022-01-29       Impact factor: 3.412

2.  A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families.

Authors:  Natividad Cuadrado-Corrales; Carolina Sánchez-Jimeno; Marta García; María-José Escámez; Nuria Illera; Angela Hernández-Martín; María-José Trujillo-Tiebas; Carmen Ayuso; Marcela Del Rio
Journal:  BMC Med Genet       Date:  2010-09-29       Impact factor: 2.103

3.  Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.

Authors:  Jose Bonafont; Angeles Mencía; Esteban Chacón-Solano; Wai Srifa; Sriram Vaidyanathan; Rosa Romano; Marta Garcia; Rosario Hervás-Salcedo; Laura Ugalde; Blanca Duarte; Matthew H Porteus; Marcela Del Rio; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther       Date:  2021-02-18       Impact factor: 12.910

4.  Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.

Authors:  Ángeles Mencía; Cristina Chamorro; Jose Bonafont; Blanca Duarte; Almudena Holguin; Nuria Illera; Sara G Llames; Maria José Escámez; Ingrid Hausser; Marcela Del Río; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther Nucleic Acids       Date:  2018-01-31       Impact factor: 8.886

Review 5.  Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease.

Authors:  Catherine Baker; Matthew S Hayden
Journal:  F1000Res       Date:  2020-04-23

6.  Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.

Authors:  Jose Bonafont; Ángeles Mencía; Marta García; Raúl Torres; Sandra Rodríguez; Marta Carretero; Esteban Chacón-Solano; Silvia Modamio-Høybjør; Lucía Marinas; Carlos León; María J Escamez; Ingrid Hausser; Marcela Del Río; Rodolfo Murillas; Fernando Larcher
Journal:  Mol Ther       Date:  2019-03-15       Impact factor: 11.454

7.  Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa.

Authors:  C Has; L Liu; M C Bolling; A V Charlesworth; M El Hachem; M J Escámez; I Fuentes; S Büchel; R Hiremagalore; G Pohla-Gubo; P C van den Akker; K Wertheim-Tysarowska; G Zambruno
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

8.  Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.

Authors:  E Chacón-Solano; C León; F Díaz; F García-García; M García; M J Escámez; S Guerrero-Aspizua; C J Conti; Á Mencía; L Martínez-Santamaría; S Llames; M Pévida; J Carbonell-Caballero; J A Puig-Butillé; R Maseda; S Puig; R de Lucas; E Baselga; F Larcher; J Dopazo; M Del Río
Journal:  Br J Dermatol       Date:  2019-04-15       Impact factor: 9.302

Review 9.  Context-Dependent Strategies for Enhanced Genome Editing of Genodermatoses.

Authors:  Oliver Patrick March; Thomas Kocher; Ulrich Koller
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

10.  Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Authors:  Cristina Chamorro; Angeles Mencía; David Almarza; Blanca Duarte; Hildegard Büning; Jessica Sallach; Ingrid Hausser; Marcela Del Río; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther Nucleic Acids       Date:  2016-04-05       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.